Hegnar Media - BerGenBio ASA Audiocast Q2 2020

Topics

• AXL drives aggressive disease

• Bemcentinib clinical development in Acute Myeloid Leukemia (AML) and Myelodysplastic syndromes (MDS)

• Bemcentinib clinical development in COVID 19

• Bemcentinib clinical development in Non Small Cell Lung Cancer (NSCLC)

• Bemcentinib Phase I/I Study in Recurrent Glioblastoma

• Bemcentininb

• Cohort A

• Cohort B

• Finance Report

• Q&A

• Q2 and recent highlights

• Q2/ H1Summary & News Flow 2020

• Questions

• Welcome